[go: up one dir, main page]

WO2010054699A1 - Conjugués de domaine de liaison d’albumine - Google Patents

Conjugués de domaine de liaison d’albumine Download PDF

Info

Publication number
WO2010054699A1
WO2010054699A1 PCT/EP2008/065691 EP2008065691W WO2010054699A1 WO 2010054699 A1 WO2010054699 A1 WO 2010054699A1 EP 2008065691 W EP2008065691 W EP 2008065691W WO 2010054699 A1 WO2010054699 A1 WO 2010054699A1
Authority
WO
WIPO (PCT)
Prior art keywords
target
capture molecule
value
albumin
molecule according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/065691
Other languages
English (en)
Inventor
Lars Abrahmsén
Caroline Ekblad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affibody AB
Original Assignee
Affibody AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody AB filed Critical Affibody AB
Priority to PCT/EP2008/065691 priority Critical patent/WO2010054699A1/fr
Publication of WO2010054699A1 publication Critical patent/WO2010054699A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells

Definitions

  • the present invention relates to the field of modulation of pharmacokinetic and pharmacodynamic properties of a target in vivo. It also relates to new methods, uses and compositions for pharmacokinetic and pharmacodynamic modulation in vivo.
  • Serum albumin is the most abundant protein in mammalian sera (40 g/l; approximately 0.7 mM in humans), and one of its functions is to bind molecules such as lipids and bilirubin (Peters T, Advances in Protein Chemistry 37:161 , 1985). Serum albumin is devoid of any enzymatic or immunological function. Furthermore, human serum albumin (HSA) is a natural carrier involved in the endogenous transport and delivery of numerous natural as well as therapeutic molecules (Sellers EM and Koch-Weser MD, Albumin Structure, Function and Uses, eds Rosenoer VM et al, Pergamon, Oxford, p 159, 1977).
  • HSA human serum albumin
  • serum albumin is directly proportional to the size of the animal, where for example human serum albumin has a half life of 19 days and rabbit serum albumin has a half life of about 5 days (McCurdy TR et al, J Lab Clin Med 143:115, 2004).
  • HSA is widely distributed throughout the body, in particular in the intestinal and blood compartments, where it is mainly involved in the maintenance of osmolarity.
  • albumins are single-chain proteins comprising three homologous domains and totaling 584 or 585 amino acids (Dugaiczyk L et al, Proc Natl Acad Sci USA 79:71 , 1982).
  • Albumins contain 17 disulfide bridges and a single reactive thiol, C34, but lack N-linked and O-linked carbohydrate moieties (Peters, 1985, supra; Nicholson JP et al, Br J Anaesth 85:599, 2000).
  • Streptococcal protein G is a bi-functional receptor present on the surface of certain strains of streptococci and is capable of binding to both IgG and serum albumin (Bj ⁇ rck et al, MoI Immunol 24:1113, 1987).
  • the structure is highly repetitive with several structurally and functionally different domains (Guss et al, EMBO J 5:1567, 1986), more precisely three Ig-binding motifs and three serum albumin binding domains (Olsson et al, Eur J Biochem 168:319, 1987).
  • M proteins comprises members that bind albumin (see e.g. Table 2 in Navarre & Schneewind, MMBR 63:174-229, 1999).
  • Non-limiting examples are proteins M1/Emm1 , M3/Emm3, M12/Emm12, Emml_55/Emm55, Emm49/Emml_49, and H.
  • the MHC class l-related neonatal Fc receptor mediates cellular trafficking and recycling of albumin and IgG (Brambell et al, Nature 203:1352- 1354, 1964; Chaudhury et al, J Exp Med 197:315-322, 2003).
  • the FcRn also known as the Brambell receptor, specifically binds albumin and IgG at acidic endosomal pH (approximately a pH of 5.5) and thus protects pinocytosed albumin and IgG from lysosomal degradation by instead transporting these back to the cell surface and releasing them at neutral pH.
  • the FcRn has an affinity for IgG and albumin in the low nanomolar and low micromolar range respectively at pH 5, but the affinity is about two orders of magnitude weaker at neutral pH (Chaudhury et al, Biochemistry 45:4983-4990, 2006; Andersen et al, Eur. J. Immunol. 36:3044-3051 , 2006). In this manner, the concentrations and the half lives of these two most abundant proteins in the plasma are regulated. Furthermore, the FcRn is responsible for actively transporting albumin and IgG over cellular barriers, e.g. the epithelium of the airways and the endothelium covering the intestines and the placenta.
  • a first aspect of the invention meets the need for novel ways of modulating the pharmacokinetics (PK) and/or pharmacodynamics (PD) of a target having a biological function in a mammal, through the provision of a capture molecule comprising i) at least one target binding moiety capable of interacting with a target, said interaction being characterized by a first K 0 value; ii) at least one albumin binding moiety capable of binding to albumin, said binding being characterized by a second K 0 value; wherein said interaction with a target at a pH value of 5.5 modulates PK and/or PD of said target in said mammal.
  • PK pharmacokinetics
  • PD pharmacodynamics
  • the aim of the PK/PD modulation is to either shorten or extend the period during which the target may exhibit a biological effect in a mammal.
  • a capture molecule according to the invention comprising at least one albumin binding moiety and at least one target binding moiety, provides a link between albumin and a target molecule.
  • the capture molecule binds albumin via its albumin binding moiety.
  • the binding between albumin and the albumin binding moiety of the capture molecule is characterized by a (second) K 0 value, i.e. a dissociation constant, which describes the affinity between the albumin and the albumin binding moiety of the capture molecule.
  • a complex may form between albumin and the capture molecule.
  • albumin is one of the most abundant proteins in plasma, the capture molecule most frequently occurs in a complex with albumin in vivo.
  • the target binding moiety and albumin binding moiety in a capture molecule according to the invention may for example be connected by covalent coupling using known organic chemistry methods, or, if one or both moieties are polypeptides, expressed as one or more fusion polypeptides in a system for recombinant expression of polypeptides, or joined in any other fashion, directly or mediated by a linker comprising a number of amino acids.
  • the capture molecule interacts with said target via the at least one target binding moiety.
  • This interaction is characterized by a (first) K 0 value, which describes the affinity between the target and the target binding moiety of the capture molecule.
  • PK and/or PD properties are hereinafter referred to as PK/PD.
  • the PK/PD modulating capture molecule is envisioned in different therapeutically relevant applications.
  • said capture molecule provides PK/PD modulation of a target by either forming (or remaining in) a complex with said target and albumin, or by releasing said target from said complex.
  • PK/PD modulation is provided by elimination of the released target from the mammal.
  • the target is directed to the subcellular lysosomes where it is degraded.
  • Increased elimination of a target such as a protein from a mammal, implies increased elimination rate of the biologically active target from the body of a mammal, as compared to a "normal" elimination rate of the target molecule per se, i.e. without previous interaction with the capture molecule.
  • elimination should be understood as removal by lysosymal degradation.
  • target half life extension implies that the elimination of a target having a biological function in a mammal is slower.
  • the target molecule thus exhibits a half life in vivo when interacting with a capture molecule according to the invention, which is longer than the half life in vivo of the target molecule in the absence of capture molecule.
  • the interaction between the FcRn receptor and albumin is considered to be involved in the PK/PD modulating effect of the capture molecule on the target.
  • an albumin- bound capture molecule is thought to take advantage of the FcRn-albumin interaction and follow the transportation of the FcRn within the cell and out of the cell.
  • the complex of capture molecule, albumin and target is protected from intracellular degradation at a pH value of around 5-6 and is subsequently transported to the cell surface through interaction with the FcRn. This interaction between the complex and FcRn mimics the naturally occurring interaction between FcRn and albumin.
  • Increased elimination is achieved by release, within a cell, of the target from the complex of FcRn, albumin, and capture molecule and subsequent elimination of the target by intracellular degradation.
  • the albumin bound capture molecule is transported to the cell surface through interaction with the FcRn.
  • the inventive capture molecule exhibits a half life in vivo similar to that of albumin. Interaction between the target and the capture molecule in vivo modulates PK/PD properties of the target while the properties of the capture molecule itself remain essentially unaffected.
  • the inventive capture molecule preferably binds endogenous albumin in vivo, such as HSA.
  • endogenous albumin in vivo
  • the manufacturing cost will be lower for the capture molecule as compared to a target-albumin fusion.
  • reducing the administered amount of synthetic substances, such as synthetic albumin fusions decreases the risk of inducing an immune response in a mammal.
  • the risk of breaking tolerance towards the endogenous protein is avoided by not incorporating endogenous protein in a fusion protein which creates new epitopes.
  • a reduced size of a drug also allows alternative formulations and ways of administration.
  • binding and “binding affinity” as used in this specification for target binding and albumin binding refer to a property of a moiety, such as a polypeptide, which may be tested for example by the use of surface plasmon resonance technology, such as in a Biacore instrument. The skilled person may then interpret the results obtained by such experiments to establish at least a qualitative measure, or to obtain a quantitative measure, for example to determine a K 0 value for the interaction between an albumin binding moiety and albumin, or between a target binding moiety and a target.
  • interaction as used in this specification refers to a pH sensitive binding between the capture molecule and the target, wherein binding is as defined above.
  • said PK/PD modulation comprises increased elimination of an active target from a mammal.
  • This embodiment concerns a capture molecule which enables release of said target from the capture molecule at a pH value of 5.5, and subsequent degradation of said target.
  • Undesired targets may for example be foreign proteins, or naturally expressed proteins that display elevated levels in plasma following a medical disorder, so that a therapeutic effect may be achieved by reducing the biological effect of said protein.
  • the undesired target is not necessarily evenly distributed in the plasma but may be concentrated in certain regions, for example around a tumor or at sites of inflammation.
  • said interaction between a target and a capture molecule allows target binding at physiological pH but results in target dissociation at a pH value of 5.5.
  • Increased elimination of a target in a mammal, such as a human being is effected through capture of the target in the blood, or in the tissue, at physiological pH and subsequent transportation along with the albumin-bound capture molecule to an intracellular degradation system.
  • FcRn receptors expressed in certain cells are thought to be involved in the underlying mechanism.
  • the complex of albumin, capture molecule and target typically enters the cell by pinocytosis or endocytosis.
  • the complex associates with FcRn in such cells and the target dissociates from the complex of FcRn, albumin, and capture molecule in the acidic environment of endosomal vesicles, i.e. an environment having a pH value of approximately 5-6, whereafter the target becomes destined for lysosomal degradation.
  • albumin with a firmly attached capture molecule, will remain bound to the FcRn, which will transport the albumin- bound capture molecule back to the cell surface for release into the extracellular space.
  • it will be available to bind another target molecule and to be reused in another elimination cycle, thereby catalyzing the elimination of the undesired target.
  • the most efficient elimination is obtained if the first K 0 value, i.e. the affinity of the capture molecule for the target, measured at physiological pH, i.e. pH 7.4, and at pH 5.5, approximately representing the pH of the endosomes, display a favourable balance.
  • Affinity at pH 7.4 should be sufficiently high to allow capture in circulation and affinity at pH 5.5 should be sufficiently low to allow release during transport inside the cell.
  • the first K 0 value i.e. the measure of the affinity of the capture molecule for said target, is lower at physiological pH than at a pH of
  • said first K 0 value at a pH value of 5.5 is at least 25 times said first K 0 value at a pH value of 7.4. Put differently, this means that the binding between the capture molecule and the undesired agent is at least 25 times stronger at physiological pH (e.g. in the extracellular space) than at a pH of 5.5 (e.g. within endosomal vesicles).
  • said first K 0 value is no more than 1 x 10 ⁇ 7 M at a pH value of 7.4, such as no more than 1 x 10 "8 M at a pH value of 7.4, for example no more than 1 x 10 "9 M at a pH value of 7.4.
  • said first K 0 value is at least 1 x 10 ⁇ 5 M at a pH value of 5.5, for example at least 1 x 10 "4 M at a pH value of 5.5.
  • both target affinity and target dissociation rate at a certain pH should be considered.
  • the early endosomes have been identified as the major sorting site for FcRn-complexes in endothelial cells and the occupation time in this compartment may be as short as a few seconds (Ober et al J.
  • the pH dependent release of the target from the capture molecule should ideally occur within this timeframe. That is, the capture molecule should display fast off-rate kinetics for its target.
  • the interaction between said target binding moiety and said target is characterized by a k O ff value at a pH value of 5.5, said k O ff being at least 1 x 10 ⁇ 3 s "1 , such as at least 1 x 10 ⁇ 2 s "1 , for example at least 1 x 10 ⁇ 1 s "1 .
  • a capture molecule wherein said interaction between said target binding moiety and said target neutralizes a biological function of the target.
  • PD properties are explicitly modulated by neutralization of a biological function of the target through interaction with the capture molecule. The neutralization may for instance be accomplished by blocking the target molecule's receptor binding site or catalytically active site.
  • a capture molecule wherein said PK/PD modulation comprises half life extension of said target in said mammal.
  • This half life related application concerns targets, for example proteins, for which the plasma levels may have been reduced following a medical disorder, or targets for which one wishes to increase the plasma level to achieve or enhance a therapeutic effect. In these scenarios, an extended half life of the target molecule is desired.
  • the half life related applications of the inventive capture molecule concern an interaction between a target and the inventive capture molecule that mimics the albumin-FcRn interaction.
  • the capture molecule binds to albumin when albumin is present.
  • the target if not already pre-mixed with the capture molecule in vitro, is either captured by the albumin bound capture molecule in the blood, i.e. at physiological pH, or later in the endosomal compartment, where it has high enough affinity to remain bound at the acidic pH. Thereafter, the target, in complex with the capture molecule and albumin, is transported back to the cell surface by FcRn mediated recycling. Thus, in this way the target is rescued from being directed to the lysosome for degradation and an extended half life is obtained.
  • the interaction between the target molecule and the capture molecule should have a low dissociation constant, K 0 , at pH 5.5 so that the half life is significantly extended.
  • K 0 dissociation constant
  • said first K 0 value is no more than 1 x 10 ⁇ 6 M at a pH value of 5.5, such as no more than 1 x 10 "7 M at a pH value of 5.5, for example no more than 1 x 10 "8 M at a pH value of 5.5, for example no more than 1 x 10 "9 M at a pH value of 5.5.
  • said first K 0 value is no more than 1 x 10 ⁇ 6 M at a pH value of 7.4, such as no more than 1 x 10 "7 M at a pH value of 7.4, for example no more than 1 x 10 "8 M at a pH value of 7.4, for example no more than 1 x 10 "9 M at a pH value of 7.4.
  • the FcRn mediated recycling back to the cell surface may last for several minutes, during which the complex is situated in an acidic environment.
  • the target molecule needs to remain bound to the capture molecule throughout the whole cycle, which implies slow off-rate kinetics.
  • said interaction between target binding moiety and target is characterized by a k O ff value at a pH value of 5.5, said k O ff being no more than 1 x 10 "3 s "1 , such as no more than 1 x 10 "4 s "1 , for example no more than 1 x 10 "5 s "1 .
  • a capture molecule wherein said interaction with a target does not affect the biological function of the target.
  • PD properties are modulated by extending the period during which the target is active. Said interaction between the capture molecule and the target thus potentiates said target by potentiation of a biological function of the target.
  • the target molecule is more likely to be fully functional when linked to endogenous or exogenous albumin via said capture molecule, as compared to situations wherein the target is covalently attached to albumin or an albumin binding molecule.
  • the affinity between the albumin binding moiety (of the capture molecule) and albumin should be such that the capture molecule essentially occurs in a complex with albumin in vivo. If the complex should dissociate, re-association is most likely to take place due to the high abundance of albumin in vivo .
  • the affinity of the albumin binding moiety (of the capture molecule) for albumin is of the same order as the affinity between the target binding moiety (of the capture molecule) and the target.
  • said second K 0 value may be no more than said first K 0 value.
  • said second K 0 value is no more than 1 x 10 "7 M, such as no more than 1 x 10 "8 M, for example no more than 1 x 10 "9 M.
  • said second K 0 value is no more than the values given above, when measured at a pH value of 5.5. This reflects the particular need for a strong affinity for albumin within the subcellular compartments. Where increased elimination of a target is desired, it is beneficial that the undesired target dissociates from the complex, while the capture molecule (via the albumin binding moiety) remains in association with albumin and hence with the FcRn receptor.
  • the capture molecule comprises at least two target binding moieties. It may be of interest to obtain even stronger binding of the target than is possible with one target binding moiety.
  • the provision of a multimer, such as a dimer, trimer or tetramer, of the target binding moiety may provide the necessary avidity effects.
  • the multimer may consist of a suitable number of target binding moieties according to the inventive capture molecule. Preferentially, the target binding moieties in such a multimer may all be identical, for example have the same amino acid sequence.
  • the linked target binding moieties in such a multimer may for example be connected by covalent coupling using known organic chemistry methods, or expressed as one or more fusion polypeptides in a system for recombinant expression of polypeptides, or joined in any other fashion, directly or mediated by a linker comprising a number of amino acids.
  • a capture molecule consisting of several identical domains of the target binding moiety linearly fused to one albumin binding moiety may, for example in an elimination related application of the inventive capture molecule, be beneficial, in particular if the target molecule is small. This may further increase the rate of elimination.
  • said albumin binding moiety is a polypeptide.
  • said albumin binding moiety may be a naturally occurring polypeptide or an albumin binding fragment thereof.
  • the albumin binding moiety may, as non-limiting examples, be selected from the group consisting of albumin binding proteins M1/Emm1 , M3/Emm3, M12/Emm12, Emml_55/Emm55, Emm49/Emml_49, H, G, MAG, ZAG, PPL and PAB.
  • the albumin binding moiety is streptococcal protein G or an albumin binding fragment or derivative thereof.
  • the albumin binding moiety is selected from the group consisting of domain GA1 , domain GA2 and domain GA3 of protein G from Streptococcus strain G148, and may thus, for example, be the GA3 domain (SEQ ID NO:491 ).
  • said albumin binding moiety is an engineered polypeptide.
  • An engineered polypeptide may be derived from a naturally occurring starting polypeptide through subjecting it to protein engineering techniques, such as mutations and alterations in a site-directed or randomized approach, with a view to create novel or enhanced properties, such as binding affinity for a molecule such as albumin.
  • said albumin binding moiety may comprise an albumin binding motif, which motif consists of the amino acid sequence:
  • X 5 is selected from Y and F;
  • X 8 is selected from N, R and S;
  • Xg is selected from V, I, L, M, F and Y;
  • Xii is selected from N, S, E and D;
  • Xi 2 is selected from R, K and N;
  • Xi 4 is selected from K and R;
  • X 20 is selected from D, N, Q, E, H, S, R and K;
  • X 23 is selected from K, I and T;
  • X 24 is selected from A, S, T, G, H, L and D;
  • X 25 is selected from H, E and D.
  • Such a polypeptide capable of binding albumin can in particular be a variant of a protein scaffold, which variant has been selected for its specific binding affinity for albumin.
  • albumin binding polypeptides are based on a statistical analysis of a large number of albumin binding polypeptides identified and characterized as described in Jonsson et a/, supra.
  • the variants are selected from a large pool of random variants of a parent polypeptide sequence or basic structure or "scaffold", said selection being based on an interaction with albumin in phage display.
  • the identified albumin binding motif, or "ABM” corresponds to the albumin binding region of the parent scaffold, which region constitutes two alpha helices within a three- helical bundle protein domain. While the original amino acid residues of the two ABM helices in the parent scaffold already constitute a binding surface for interaction with albumin, that binding surface is modified by the substitutions according to the invention to provide an alternative albumin binding ability.
  • the function of any polypeptide is dependent on the tertiary structure of the polypeptide. It is therefore possible to make minor changes to the sequence of amino acids in a polypeptide without affecting the function thereof.
  • the polypeptide moiety according to this embodiment encompasses modified variants of the ABM, which are such that the albumin binding characteristics are retained. For example, it is possible that an amino acid residue belonging to a certain functional grouping of amino acid residues (e.g. hydrophobic, hydrophilic, polar etc) could be exchanged for another amino acid residue from the same functional group.
  • X 5 is Y.
  • Xs is selected from N and R, and may in particular be R.
  • Xg is L.
  • Xn is selected from N and S, and may in particular be N.
  • X12 is selected from R and K, such as X12 being R or Xi2 being K.
  • Xi 4 is K.
  • X 2 o is selected from D, N, Q, E, H, S and R, and may in particular be E.
  • X23 is selected from K and I, and may in particular be K.
  • X 24 is selected from A, S, T, G, H and L.
  • X2 4 is L.
  • X23X24 is KL. In another even more specific embodiment of the albumin binding moiety of the PK/PD modulating capture molecule, X23X24 is TL.
  • X2 4 is selected from A, S, T, G and H.
  • X2 4 is selected from A, S, T, G and H
  • X25 is H.
  • albumin binding motif ABM sequences. These sequences constitute individual embodiments of the ABM sequence in the above definition of possible albumin binding moieties according to the PK/PD modulating capture molecule.
  • the sequences of individual albumin binding motifs are presented in Figure 1 and as SEQ ID NO:1 -245 and 496.
  • the ABM consists of an amino acid sequence selected from SEQ ID NO:1 -245 and 496.
  • the ABM sequence defining the albumin binding moiety is selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:15, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:35, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:155, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241 , SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244 and SEQ ID NO:245.
  • the ABM sequence is selected from SEQ ID NO:3, SEQ ID NO:35, SEQ ID NO:53 and SEQ ID NO:239.
  • the ABM may form part of a three-helix bundle protein domain.
  • the ABM may essentially constitute or form part of two alpha helices with an interconnecting loop, within said three-helix bundle protein domain.
  • such a three-helix bundle protein domain is selected from the group consisting of three-helix domains of bacterial receptor proteins.
  • Non-limiting examples of such bacterial receptor proteins may be selected from the group consisting of albumin binding receptor proteins from species of Streptococcus, Peptostreptococcus and Finegoldia, such as for example selected from the group consisting of proteins G, MAG, ZAG, PPL and PAB.
  • the ABM forms part of protein G, such as for example protein G from Streptococcus strain G148.
  • the three-helix bundle protein domain of which the ABM forms a part is selected from the group consisting of domain GA1 , domain GA2 and domain GA3 of protein G from Streptococcus strain G148, in particular domain GA3.
  • the ABM forms part of one of the five three-helix domains of the bacterial receptor protein A from Staphylococcus aureus; i.e. the three-helix bundle protein domain is selected from the group consisting of protein A domains A, B, C, D and E.
  • the ABM forms part of protein Z, derived from domain B of protein A from Staphylococcus aureus.
  • the albumin binding moiety of the PK/PD modulating capture molecule wherein the ABM "forms part of a three-helix bundle protein domain, this is understood to mean that the sequence of the ABM is "inserted” into or “grafted” onto the sequence of the naturally occurring (or otherwise original) three-helix bundle domain, such that the ABM replaces a similar structural motif in the original domain.
  • the ABM is thought to constitute two of the three helices of a three-helix bundle, and can therefore replace such a two-helix motif within any three-helix bundle.
  • the replacement of two helices of the three-helix bundle domain by the two ABM helices has to be performed so as not to affect the basic structure of the polypeptide. That is, the overall folding of the Ca backbone of the polypeptide moiety capable of binding albumin will be substantially the same as that of the three-helix bundle protein domain of which it forms a part, e.g. having the same elements of secondary structure in the same order etc.
  • an ABM according to these embodiments of the albumin binding moiety of the PK/PD modulating capture molecule "forms part" of a three-helix bundle domain if the polypeptide according to this embodiment has the same fold as the original domain, implying that the basic structural properties are shared, those properties e.g.
  • the albumin binding polypeptide is a three-helix bundle protein domain, which comprises the albumin binding motif as defined above and additional sequences making up the remainder of the three-helix configuration.
  • the PK/PD modulating capture molecule may comprise an albumin binding polypeptide, which comprises the amino acid sequence:
  • [ABM] is an albumin binding motif as defined above,
  • Xa is selected from V and E; Xb is selected from L, E and D; X 0 is selected from N, L and I; Xd is selected from R and K; and Xe is selected from D and K.
  • X 3 is V. In one embodiment, X b is L.
  • X 0 is N. In one embodiment, X d is R. In one embodiment, X e is D.
  • albumin binding polypeptide sequences constitute individual examples of the albumin binding moiety according to the above embodiment of the capture molecule.
  • the sequences of these individual albumin binding polypeptides are presented in Figure 1 and as SEQ ID NO:246-490.
  • the sequence of the albumin binding polypeptide is selected from SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:254, SEQ ID NO:260, SEQ ID NO:270, SEQ ID NO:272, SEQ ID NO:280, SEQ ID NO:291 , SEQ ID NO:294, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:300, SEQ ID NO:400, SEQ ID NO:484, SEQ ID NO:485, SEQ ID NO:486, SEQ ID NO:487, SEQ ID NO:488, SEQ ID NO:489 and SEQ ID NO:490 and sequences having 85 % or greater identity thereto.
  • the sequence of the albumin binding polypeptide is selected from SEQ ID NO:248, SEQ ID NO:280, SEQ ID NO:298 and SEQ ID NO:484 and sequences having 85 % or greater identity thereto.
  • the present invention in addition to a polypeptide whose amino acid sequence is selected from SEQ ID NO:246-490 or a subset thereof, also encompasses variants thereof.
  • the amino acid sequences of such encompassed variants exhibit small differences only in comparison with SEQ ID NO:246-490.
  • One definition of such variants is given above, i.e. an albumin binding polypeptide with an amino acid sequence having at least 85 % identity to a sequence selected from SEQ ID NO:246- 490.
  • the polypeptide may have a sequence which is at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 % or at least 99 % identical to the sequence selected from SEQ ID NO:246-490.
  • the comparison may be performed over a window corresponding to the shortest of the sequences being compared, or over a window corresponding to an albumin binding motif in at least one of the sequences being compared.
  • the albumin binding moiety binds to human serum albumin.
  • the albumin binding moiety is capable of interacting with at least one of, and preferably all of, residues F228, A229, A322, V325, F326 and M329 in human serum albumin so as to enhance binding of the molecule to albumin.
  • the albumin binding moiety may include an amino acid residue which forms an interaction with the M329 residue in human serum albumin so as to enhance binding of the molecule to albumin.
  • the albumin binding moiety may include an amino acid residue which forms an interaction with helix 7 in the human serum albumin domain MB so as to enhance binding of the molecule to albumin.
  • the albumin binding moiety includes an amino acid residue which forms an interaction with residues in human serum albumin domain MA so as to enhance binding of the molecule to albumin.
  • the albumin binding moiety includes an amino acid residue which forms an interaction with residues between helices 2 and 3 of human serum albumin so as to enhance binding of the molecule to albumin.
  • the target binding moiety is a polypeptide.
  • said target binding moiety may be a naturally occurring polypeptide or a target binding fragment thereof, such as the ectodomain of a receptor, such as VEGFr, or an enzyme, such as carboxypeptidase N.
  • the target binding polypeptide may include a three-helix bundle protein domain.
  • the target binding motif of a target binding moiety may essentially constitute two alpha helices with an interconnecting loop, within said three-helix bundle protein domain.
  • such a three-helix bundle protein domain is selected from the group consisting of three-helix domains of bacterial receptor proteins.
  • Non-limiting examples of such bacterial receptor proteins are the five different three-helical domains of protein A from Staphylococcus aureus, and derivates thereof.
  • the polypeptide includes a variant of protein Z, derived from domain B of protein A from Staphylococcus aureus.
  • said target binding moiety is an engineered polypeptide.
  • the target binding moiety may for example be an engineered ectodomain of a receptor, such as VEGFr, or an engineered enzyme, such as carboxypeptidase N.
  • said target binding moiety may be a variant of a protein scaffold, which variant has been selected for its specific binding affinity for said target.
  • Non-limiting examples of polypeptide moieties capable of binding to a target are selected from the group consisting of antibodies and fragments and domains thereof substantially retaining antibody binding activity; microbodies, maxybodies, avimers and other small disulfide-bonded proteins; and variants of binding proteins derived from a scaffold selected from the group consisting of staphylococcal protein A and domains thereof, and lipocalins, ankyrin repeat domains, cellulose binding domains, Y crystallines, green fluorescent protein, human cytotoxic T lymphocyte-associated antigen 4, protease inhibitors, PDZ domains, peptide aptamers, staphylococcal nuclease, tendamistats, fibronectin type III domain, zinc fingers, conotoxins, and Kunitz domains.
  • said variants of a target binding protein derived from a scaffold include variants of protein Z, such as the variants presented in Figure 1 and also as SEQ ID NO:492 and 493, derived from a common scaffold and originating from domain B of protein A from Staphylococcus aureus.
  • the generalized amino acid sequence of such a Z derived scaffold is presented in Figure 1 (denoted "Scaffold 1 ") and as SEQ ID NO:494, wherein each X individually corresponds to an amino acid residue which is varied.
  • each X may be any amino acid residue independent of the identity of any other residue denoted X in the sequence.
  • said Z variants can be derived from a scaffold variant which has been engineered in such a way as to provide novel or improved properties, such as improved structural and chemical stability.
  • the generalized amino acid sequence of such a Z derived engineered scaffold is presented in Figure 1 (denoted "Scaffold 2") and as SEQ ID NO:495 wherein each X individually corresponds to an amino acid residue which is varied. Each X may be any amino acid residue as described above.
  • said albumin binding moiety is a polypeptide and said target binding moiety is a polypeptide.
  • said at least one target binding moiety and at least one albumin binding moiety are covalently coupled.
  • Said target binding moiety and said albumin binding moiety may form, for example, a fusion complex or a conjugated complex.
  • aspects of the present invention provide a polynucleotide encoding a capture molecule as described above, i.e. when the albumin binding moiety and the target binding moiety respectively are polypeptides, as well as an expression vector comprising the polynucleotide and a host cell comprising the expression vector.
  • the latter three aspects of the invention are tools for the production of a capture molecule comprising polypeptide moieties as described above, and the skilled person will be able to obtain them and put them into practical use without undue burden, given the information herein concerning the capture molecule that is to be expressed and given the current level of skill in the art of recombinant expression of proteins.
  • another related aspect of the invention is a method of producing a capture molecule according to the invention, comprising expressing a polynucleotide as herein described, for example via the culturing of a host cell as herein defined under conditions permitting expression of the capture molecule from the expression vector, and isolating the capture molecule.
  • Yet another aspect of the present invention concerns a capture molecule as defined above for use as a medicament.
  • a further aspect of the present invention concerns a method of producing a capture molecule wherein said target binding moiety is a polypeptide, comprising i) providing a library of potential target binding moieties; ii) selecting a target binding moiety capable of a PK/PD modulating interaction with a target, wherein said selection comprises at least the steps of binding, wash and elution, and wherein said binding is performed at a first pH, said wash is performed at a second pH and said elution is performed at a third pH; iii) providing an albumin binding moiety; and iv) coupling said binding moieties.
  • the inventive method involves providing a library of polypeptide moieties potentially capable of binding a target. From the library of potential target binding moieties, actual binding moieties capable of PK/PD modulating interaction with a target are extracted. This is accomplished by selection of at least one such binding moiety. The selection comprises the steps of binding, wash and elution, wherein the first two steps, i.e. binding and wash, are performed at a first pH value and the last step, i.e. elution, is performed at a second pH value. After selection of a suitable binding moiety, an albumin binding moiety is provided and the two moieties are coupled to provide a capture molecule.
  • said first pH is physiological pH, i.e. a pH value of around 7.4.
  • the wash and elution conditions are adapted so as to obtain binding moieties that have either a strong affinity or a low to no affinity for the target at pH 5.5.
  • said second pH i.e. wash pH
  • said third pH may be 7.4.
  • elution pH may be 5.5.
  • Using a combination of wash at pH 7.4 and elution at pH 5.5 will yield a fraction eluted at pH 5.5 comprising target binding moieties that may be suitable for elimination applications.
  • said second pH i.e. wash pH
  • the third pH i.e. elution pH
  • elution pH may be lower than 5, such as lower than 3, such as 2.2.
  • a target binding moiety may be selected in parallel selections depending on the application of the capture molecule.
  • the selections are performed in parallel, with buffers having pH values mimicking the extracellular and the endosomal environment respectively. That is, target binding moieties enriched in selections performed at pH 5.5 may be suitable for extended half life applications, whereas target binding moieties enriched in selections performed at pH 7.4 may be suitable for elimination applications.
  • Selection of pH sensitive binders for the target of interest is typically performed using a phage display library of potential target binding moieties, such as for example a library of Z variants as described in Example 2 and 3.
  • a PK/PD modulating interaction between a target binding moiety and a target may for example originate from a pH sensitive binding interface having one or more histidine residues either in the target molecule or in the target binding moiety of the capture molecule.
  • a target binding moiety for the target of interest is available, for instance a Z variant e.g. derived from a phage display selection
  • a pH-sensitive interaction may be designed on the amino acid sequence level by rational introduction of one or more histidine residues situated at the binding interface. Selection of candidate residues is simplified if a three-dimensional model structure of the complex of target and target binding moiety is available.
  • charge-charge interactions at the binding surface will guide the choice of where to introduce histidine residues causing either electrostatic repulsion or attraction as the pH is lowered.
  • Replacements of amino acid residues are readily achieved by standard mutagenesis techniques.
  • the binding kinetics and affinity for the target molecule would be measured at pH 5.5 and 7.4, for instance by biosensor analysis. If no capture molecule is available, then such a molecule can be developed de novo using phage display selection at different pH conditions, for example as described in Examples 2 and 3. This would be followed by screening for pH-sensitive binding moieties as above, followed by additional biosensor analysis to assess functional interference, for instance blocking of the target molecule's receptor binding site.
  • the capture molecule is suitably designed in a way such that no interference occurs with the albumin-FcRn interaction. That is, sterical hindrance or allosteric effects are avoided.
  • a set of Z variants (as target binding moieties) fused to ABD variants (as albumin binding moieties) were tested in binding experiments with albumin and FcRn. The binding experiments showed that the ABD fused Z variants do not interfere with the albumin-FcRn interaction.
  • a pharmaceutical preparation for the elimination of an undesired target from a mammal through transport of said target to an intracellular degradation system comprising i) a capture molecule as described above in connection with elimination related applications of the invention; and ii) pharmaceutically acceptable excipients.
  • the capture molecule comprised in the inventive pharmaceutical preparation will, upon administration to a mammalian host, associate with albumin already present in the host via the binding affinity of the albumin binding moiety to form a non-covalent complex.
  • said complex is formed in vitro through the addition of exogenous albumin to the inventive pharmaceutical preparation itself, which then comprises albumin in a non- covalent complex with the capture molecule as described above.
  • the pharmaceutical preparation may be in a form suitable for injection.
  • the pharmaceutical preparation may be in a form suitable for uptake over an epithelial barrier.
  • it may take the form of an aerosol formulation, for oral or nasal inhalation, or an oral formulation enabling intestinal absorption.
  • a method of treatment of a mammal through the elimination of an undesired target from said mammal comprising administering a pharmaceutical preparation as described immediately above to said mammal, whereby i) said capture molecule captures said target, and optionally associates with albumin via said albumin binding moiety, in an extracellular space at a first pH value, thus forming a complex of target, capture molecule and albumin, ii) said complex is transported into a cell expressing FcRn receptors, thus becoming located in an intracellular space at a second pH value; iii) said complex is bound to said FcRn receptor at said second pH value, said target dissociates from said complex and is transported to an intracellular degradation system.
  • the capture molecule will escape degradation and will be safely recycled back to the cell surface along with the albumin-FcRn complex.
  • the capture molecule preferably neutralizes a biological function of the target, for example by blocking the receptor binding site or catalytically active site on the target.
  • said first pH value is physiological pH, i.e. a pH of around 7.4, such as is typical for the extracellular space of a mammalian host.
  • said second pH value is in the range of 5-6, such as is typical for intracellular vesicles (endosomes) involved in the processes of endocytosis and pinocytosis.
  • Another elimination related aspect of the invention provides a capture molecule, as described in connection with elimination related applications of the invention, for treatment of a mammal through the elimination of an undesired target from said mammal.
  • Another elimination related aspect of the invention provides the use of a capture molecule, as described in connection with elimination related applications of the invention, for the preparation of a medicament for treatment of a mammal through the elimination of an undesired target from said mammal.
  • Some elimination related aspects of the present invention concern removal of undesired targets from a mammal, such as from the circulation or tissue, by increased elimination of such undesired targets.
  • This may for example be foreign proteins, or naturally expressed proteins that display elevated levels in plasma following a medical disorder and where a therapeutic effect may be achieved by, optionally, neutralizing the biological effect of said protein followed by elimination of said protein.
  • the undesired target is not necessarily evenly distributed in the plasma but may be concentrated in certain regions, for example around a tumor or at sites of inflammation.
  • the target with which the capture molecule interacts may be any molecule having an undesired biological function or effect in a mammal.
  • Non-limiting examples of such target molecules are selected from the group consisting of TGF ⁇
  • transforming growth factor beta transforming growth factor beta
  • a ⁇ peptide other disease-associated amyloid peptides
  • toxins such as bacterial toxins and snake venoms
  • blood clotting factors such as von Willebrand factor
  • interleukins such as IL-13 and IL-2
  • myostatin pro-inflammatory factors, such as TNF- ⁇ (tumor necrosis factor alpha), TNF- ⁇ receptor and IL-8 (interleukin 8); complement factors, such as C3a and C5a; hypersensitivity mediators, such as histamine and IgE; hGH (human growth hormone).
  • inventive method or use can be applied when said mammal for example suffers from a condition selected from cardiovascular disease, Alzheimer's disease, growth deficiencies, hypersensitivity, anaphylactic shock, muscle wasting disease, renal dysfunction, hemophilia, diabetes, sepsis and cancer diseases.
  • inventive method or use are suitable for any medical or other condition where elimination of a target is beneficial to the host.
  • a pharmaceutical preparation for extending the half life of a target in a mammal through transport of said target from an intracellular space, said preparation comprising i) a capture molecule as described above in connection with half life related applications of the invention; and ii) pharmaceutically acceptable excipients.
  • the capture molecule comprised in the inventive pharmaceutical preparation according to this aspect will, upon administration to a mammalian host, associate with any target already present in the host via the binding affinity of the target binding moiety to form a non-covalent complex.
  • said complex is formed in vitro through the addition of said target to the inventive pharmaceutical preparation itself, which then comprises said target in a non-covalent complex with the capture molecule described above.
  • the target and the capture molecule remain in a complex upon administration to avoid a situation where the target dissociates from the capture molecule and is not recaptured in vivo due to dilution effects.
  • the capture molecule may exhibit a sufficiently strong affinity for the target molecule for the capture molecule to remain associated with the target at physiological pH, such as in the circulation.
  • the capture molecule will, upon administration of the pharmaceutical preparation, associate with albumin already present in the mammalian host via the albumin binding moiety of the capture molecule.
  • said association of albumin and capture molecule can take place in vitro through the addition of albumin to the inventive pharmaceutical preparation.
  • the capture molecule optionally may associate with the target and/or albumin in vitro, and/or optionally may associate with the target and/or albumin in vivo.
  • the pharmaceutical preparation may be in a form suitable for injection.
  • the pharmaceutical preparation may be in a form suitable for uptake over an epithelial barrier.
  • it may take the form of an aerosol formulation, for oral or nasal inhalation, or an oral formulation enabling intestinal absorption.
  • a method of treatment of a mammal through extending the half life of a target in vivo comprising administering a pharmaceutical preparation, as described immediately above, to said mammal, whereby i) said preparation optionally captures said target via said capture molecule, and optionally associates with albumin via said albumin binding moiety, thus forming a complex of target, capture molecule and albumin, ii) if said complex is located in a cell at a first pH value, it is transported out of the cell, via interaction between said albumin and an FcRn receptor, thus becoming located in an extracellular space at a second pH value, and optionally iii) said target dissociates from said complex in said extracellular space.
  • said target is captured by the capture molecule in vivo.
  • said capture molecule is not already associated with exogenous albumin in vitro, such association with endogenous albumin occurs upon administration of the preparation to said mammal.
  • the target, associated in said complex with capture molecule and albumin is rescued from intracellular degradation through transport out of the cell by interaction between albumin and FcRn, in a manner mimicking the interaction between FcRn and albumin (or IgG).
  • said first pH value is in the range of 5-6, such as is typical for intracellular vesicles (endosomes) involved in the processes of endocytosis and pinocytosis.
  • said second pH value is physiological pH, i.e. a pH of around 7.4, such as is typical for the extracellular space of a mammalian host.
  • a capture molecule as described in the half life related applications of the invention, for treatment of a mammal through extending the half life of a target in said mammal.
  • a capture molecule as described in the half life related applications of the invention, for the preparation of a medicament for treatment of a mammal through extending the half life of a target in said mammal.
  • targets such as proteins
  • targets typically exhibit reduced plasma levels as a result of a medical disorder in a mammalian host.
  • target plasma levels need to be increased in order to achieve or potentiate a therapeutic effect, or short-lived therapeutics need extended circulation time.
  • hGH see Example 7 below
  • TGF ⁇ see Example 8 below
  • G-CSF for treatment of neutropaenia in AIDS or after chemotherapy or bone-marrow transplantation
  • insulin and GLP-1 for treatment of type I and type Il diabetes respectively
  • IFN- ⁇ for treatment of chronic hepatitis C
  • interleukins such as interleukin-2 for treatment of cancers such as malignant melanoma and renal cell cancer.
  • Figure 1 shows the sequences of individual albumin binding motifs SEQ ID NO:1 -245 and 496, individual albumin binding polypeptides SEQ ID NO:246-491 , Z variants SEQ ID NO:492-493 and Z scaffold variants SEQ ID NO:494-495.
  • Figures 2A-F show the results of the additive ELISA analysis performed at pH 6.0 (squares) and pH 7.4 (triangles) as described in Example 1 , using an albumin binding moiety alone or comprised in a capture molecule. The results are shown as absorbance at a wavelength of 620 nm.
  • Wells were coated with increasing concentrations of albumin binding moieties ABDwt (A) and ABD035 (B) alone; and with increasing concentrations of capture molecules Z00342-ABDwt (C), ABDwt-Z00342 (D), (Z00342) 2 -ABDwt (E) and Z02891-ABD035-cys-Mal-DOTA (F).
  • Figures 3A-E show the results of SPR analysis performed at pH 6.0 as described in Example 1 , using an albumin binding moiety alone or comprised in a capture molecule.
  • the analysis was performed using ABDwt (A), Z00342- ABDwt (B), ABDwt-Z00342 (C), (Z00342) 2 -ABDwt (D) and Z02891 -ABD035- cys-Mal-DOTA (E).
  • HSA broken line
  • HSA and capture molecule solid line
  • albumin binding moiety alone were injected over a surface with immobilized FcRn.
  • Example 1 Effect of different ABD-fused Z variants on the albumin-FcRn interaction
  • a set of capture molecules consisting of target binding Z variants fused to albumin binding domains (ABD) were tested in interaction studies between albumin and FcRn performed with ELISA and Biacore at pH 6 and at pH 7.4.
  • Z00342 SEQ ID NO:492
  • Z02891 SEQ ID NO:493
  • ABD035 is an affinity matured variant of wild-type ABD (ABD w t, SEQ ID NO:491 ) as described in Jonsson et al, supra.
  • Fusion proteins were produced with recombinant DNA technology and purification was performed using affinity capture on HSA-sepharose (GE Healthcare) and reverse phase chromatography.
  • Maleimido-mono-amide- DOTA (Macrocyclics, cat. no. B-272) conjugation of ABD035 was performed in 0.2 M NaAc, pH 5.5, for 60 min at 37 0 C and with 3x molar excess of MaI- DOTA.
  • Conjugated molecules were separated from unconjugated molecules and free MaI-DOTA by reverse phase chromatography.
  • CM5 sensor chips were coupled with ShFcRn-GST (-600-1000 RU) using amine coupling chemistry according to the manufacturer's instructions. The coupling was performed by injecting 10- 12 ⁇ g/ml of each protein into 10 mM sodium acetate, pH 4.5 (GE Healthcare). All experiments were performed in phosphate buffer (67 mM phosphate buffer, 0.15 M NaCI, 0.005% Tween20) at pH 6.0.
  • Portions of 1 ⁇ M of size exclusion chromatography isolated monomeric HSA (Sigma-Aldhch) or mouse serum albumin (MSA, Calbiochem) were injected, alone or together with one of the molecules 1 , 3, 4, 5 and 6 (1 -2 ⁇ M), over immobilized receptors with a flow rate of 40 ⁇ l/min at 25 0 C.
  • the surfaces were gently regenerated by dissociation of bound molecules using buffer at pH 6.0.
  • Albumin binding moieties alone were injected over immobilized receptors as controls. In all experiments, data were zero adjusted and the reference cell value subtracted. Binding analyses were performed using the BIAevaluation wizard (GE Healthcare).
  • Z variants fused to ABD do not interfere with the albumin- FcRn interaction and allow a flexible design of the capture molecule in terms of the arrangement of the ABD relative to the Z variant.
  • the same results were obtained when using mouse FcRn and rat FcRn (data not shown). This validates the molecules for in vivo studies in these animals in order to evaluate the half life of capture molecules according to the present invention.
  • Example 2 Phage display selection of Z variants having a low affinity for target at pH 5.5
  • Biotinylation of target A target protein, or a domain or a peptide thereof, is biotinylated for 30 min at room temperature using EZ-LinkTM-Sulfo-NHS-LC- Biotin (Pierce, cat. no. 21335) in a 10-fold molar excess of biotin in PBS (2.68 mM KCI, 1.47 mM KH 2 PO 4 , 137 mM NaCI, 8.1 mM Na 2 HPO 4 , pH 7.4). Buffer exchange and removal of excess biotin is performed on a protein desalting column (Pierce, cat. no. 89849) using the PBS buffer above.
  • Phage display selection A phage library, prepared essentially as described in Nord et a/ (Prot Eng 8:601-608, 1995), is used for selection. Alternatively, a library enriched for histidine residues in the variable positions is likewise created and used. The latter may be accomplished by designing the oligonucleotides for the initial library construction such that the allowed codon combination results in a bias, such as 15 %, for histidine residues in each of the variable positions. Preparation of phage stocks from the library and between selections is performed according to previously described procedures (Nord et al, Nat. Biotechnol. 15:772-777, 1997) using the helper phage M13K07 (New England Biolabs, Beverly, MA, USA) and PBS, pH 7.4.
  • Selection and wash are performed at physiological pH, but the elution conditions are adapted so as to obtain binders that have low to no affinities for the target at pH 5.5.
  • Several rounds of selection using increasingly stringent conditions, such as lowering the target concentration and harsher washing conditions, are performed in solution and the bound phages are captured on streptavid in-coated paramagnetic beads (Dynabeads M-280 Streptavidin; Dynal cat. no. 112.06).
  • streptavid in-coated paramagnetic beads Dynabeads M-280 Streptavidin; Dynal cat. no. 112.06
  • all tubes used in this procedure are pretreated with PBS-T (0.5 % Tween 20 in PBS) supplemented with 0.1 % gelatin, and the phage stocks are pre-incubated with streptavidin beads for the first two rounds of selection.
  • phages are eluted in a buffer at pH 5.5 (e.g. 50 mM acetate, 150 mM NaCI) for 10 minutes, after which the pH is adjusted to 7.4. In each round of selection, the eluted fraction is kept and used for the next round. Eluted phages are subsequently used to infect cultures of log phase E. coli RR1 ⁇ M15 cells.
  • pH 5.5 e.g. 50 mM acetate, 150 mM NaCI
  • the cells are pelleted by centrifugation, dissolved in a small volume of TSB-YE and spread on TYE agar plates (15 g/l agar, 3 g/l NaCI, 10 g/l tryptone and 5 g/l yeast extract), supplemented with 2 % glucose and 100 mg/l ampicillin, and incubated over night at 37 0 C.
  • TYE agar plates 15 g/l agar, 3 g/l NaCI, 10 g/l tryptone and 5 g/l yeast extract
  • ELISA ELISA positive clones are sequenced using ABI PRISM dGTP, BigDye Terminator v3.0 Ready Reaction Cycle Sequencing Kit (Applied Biosystems) according to the manufacturer's recommendations. Purified sequencing reactions are analyzed on an ABI Prism® 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and cluster analysis is performed to identify relevant variants, targeting one or more epitopes.
  • Z variants enriched in fractions eluted at pH 5.5 may be suitable for elimination applications.
  • Z variants of interest are cloned as fusions to an appropriate albumin binding domain and recombinantly expressed, purified and characterized further as described in Example 4. These candidates do not necessarily contain histidine residues, since a pH sensitive interaction may also originate from histidine residues in the target molecule.
  • Example 3 Phage display selection of Z variants having a high affinity for target at pH 5.5
  • Target protein or domain or peptide thereof, is biotinylated as described in Example 2.
  • Phage display selection Phage libraries and phage stocks are prepared essentially as described in Example 2. The selection is performed at physiological pH, but the washing and elution conditions are adapted so as to obtain binders that have high affinities for the target at pH 5.5. Several rounds of selection, using increasingly stringent conditions such as lowering the target concentration and harsher washing conditions, are performed in solution and the bound phages are captured on streptavid in-coated paramagnetic beads (Dynabeads M-280 Streptavidin; Dynal cat. no. 112.06).
  • Eluted phages are subsequently used to infect cultures of log phase E. coli RR1 ⁇ M15 cells. After 30 min of incubation, the cells are pelleted by centhfugation, dissolved in a small volume of TSB-YE and spread on TYE agar plates (15 g/l agar, 3 g/l NaCI, 10 g/l tryptone and 5 g/l yeast extract), supplemented with 2 % glucose and 100 mg/l ampicillin, and incubated over night at 37 0 C.
  • Z variants enriched in the fraction resisting elution at pH 5.5 may be suitable for extended half life applications.
  • Z variants of interest are cloned as fusions to an appropriate albumin binding domain and recombinantly expressed, purified and characterized further as described in Example 4. These candidates do not necessarily contain histidine residues, since a pH sensitive interaction may origin from histidine residues in the target molecule.
  • Z variants selected as described in Examples 2 or 3, or previously selected variants that have been subjected to rational mutagenesis, are fused to an appropriate albumin binding moiety, for example as described in Example 1.
  • the resulting capture molecules are characterized by biosensor analysis on a Biacore 2000 instrument (GE Healthcare).
  • the target protein is immobilized on CM-5 chips (GE Healthcare) by amine coupling chemistry according to the manufacturer's instructions.
  • Buffers 50 mM sodium phosphate, 150 mM NaCI, 0.005 % surfactant P20
  • the candidate capture molecules diluted in either buffer are injected over the flow cells in concentration ranges as appropriate.
  • the candidate capture molecule is first injected in the buffer at pH 7.4, and about 10 min post injection the buffer is changed to pH 5.5 for up to 15 min.
  • the capture molecule should ideally dissociate immediately when the pH is changed from 7.4 to 5.5, and the K 0 should be no more than 1 x 10 ⁇ 7 M at pH 7.4, with no detectable binding in biosensor analysis at pH 5.5. In this application, fast off-rate kinetics are also desired.
  • capture molecules that have a K 0 of no more than 1 x 10 ⁇ 6 at pH 5.5 will be selected for further analysis.
  • promising candidates may be further modified by site-directed mutagenesis and reanalyzed for their pH-sensitive binding.
  • Example 5 Investigating the in vitro half life of a target molecule having a pH sensitive interaction with an albumin binding capture molecule
  • the target molecule is labeled with radioactivity and added to cell cultures, alone or together with the capture molecule pre-incubated with albumin.
  • Radiolabeling of target molecule Radiometal labeling may be the method of choice since radiolabeled catabolites will be trapped in the cell upon lysosomal degradation.
  • the target molecule is dissolved in, or buffer exchanged into, 0.07 M borate buffer, pH 9.2.
  • Freshly prepared CHX-A"- DTPA (Macrocyclics, Dallas, US, Cat No B-355) 1 mg/ml, in 0.7 M borate buffer pH 9.2, is added to target at a 1 :1 molar ratio and the mixture is incubated at 37 0 C for 3 h. Buffer exchange to 0.2 M ammonium acetate, pH 5.5, is performed on a NAP-5 column (GE Healthcare, cat. no.
  • the CHX-A"-DTPA conjugated target molecule is mixed with a radionuclide such as 111 In (for example 111 InCI 3 , Malinckrodt/Covidien, Hazelwood, US, Cat No N132F0), diluted in hydrochloric acid. Approximately 4 MBq per nmol of the target molecule is used and the mixture is incubated at room temperature for 30 min.
  • 111 In for example 111 InCI 3 , Malinckrodt/Covidien, Hazelwood, US, Cat No N132F0
  • a 1 ⁇ l aliquot is analysed by ITLC SG (instant thin layer chromatography, Gelman Sciences Inc.), eluted with 0.2 M citric acid and analyzed in a phosphor imager (for example CycloneTM Storage Phosphor System, PerkinElmer, Waltham, US). If the concentration of labeled target molecule exceeds 95 % of the population, the sample is used directly. Otherwise, free radiometals are removed using a NAP-5 column as described above.
  • ITLC SG instant thin layer chromatography, Gelman Sciences Inc.
  • a phosphor imager for example CycloneTM Storage Phosphor System, PerkinElmer, Waltham, US.
  • Antigen presenting cells such as the monocytic cell lines U293 or THP- 1 , are selected for the study, since these cells readily engulf extracellular components by non-specific pinocytosis and have been shown to express FcRn.
  • Cell cultures are established in RPMI 1640 medium (GIBCO, cat. no. 3187-25) with 10 % FCS (Fetal calf serum; GIBCO, cat. no. 10108-165), but this is changed to serum free medium just before the start of the experiment.
  • two cell populations will be compared: cultures with 1 ) labeled target molecule and 2) labeled target molecule and a 10-fold molar excess of the capture molecule pre- incubated in a 10-fold molar excess of albumin. 10 pmol/ml of the target molecule is added in the initial experiment. After, for instance, 1 , 12, 24 and 48 h (separate cell populations are prepared for each time point) the medium is withdrawn and the cells are harvested and washed 3 times with fresh medium. Radioactivity in the medium and the cells is measured using an automated gamma counter equipped with a 3-inch NaI (Tl) detector (1480 WIZARD OY, Wallac, Turku, Finland).
  • Tl 3-inch NaI
  • BSA bovine serum albumin
  • Example 6 Investigating the in vivo half life of a target molecule with a pH sensitive interaction with an albumin binding capture molecule
  • a comparative study of the half life, modulated by interaction with capture molecules as described herein, may also be performed in vivo. If the size of the target molecule is ⁇ 60 kDa the half life may be investigated per se.
  • Radiolabeling of target molecule is carried out as described in Example 5.
  • mice In a comparative study, the target molecule is radiolabeled and administrated to mice with or without (control) the albumin- binding capture molecule. For each capture molecule, two populations of mice (n>6) are injected via the tail vein according to the following suggested scheme:
  • Population B Premix of: 1 ) non-labeled albumin binding capture molecule, 10-fold molar excess compared to target molecule 2) radiolabeled target molecule, 1 -3 ⁇ g
  • Blood sample analysis Blood samples are withdrawn, e.g. at 0.25, 0.5, 1 , 2 , 4, 8, 24, 40 and 48 h post injection, and collected in pre-weighed heparin treated vials. The samples are weighed and radioactivity in whole blood is measured using an automated gamma counter equipped with a 3-inch NaI (Tl) detector (1480 WIZARD OY, Wallac, Turku, Finland). The percent of injected activity per gram (% lA/g) is calculated for each sample.
  • the target molecule in the population co-administered with the capture molecule indicates an extended circulation time of the target molecule achieved by a pH resistant binding to the capture molecule within the acidic endosome and by albumin- FcRn mediated recycling.
  • the target molecule is ⁇ 60 kDa, the half life calculated in a pharmacokinetic analysis is compared to the half life limited by renal clearance.
  • Example 7 Exploiting an albumin binding capture molecule to regulate the plasma levels of active human growth hormone
  • the human growth hormone is produced in the pituitary gland and functions to regulate tissue growth and metabolism, mainly by stimulating the production of IGF-I and IGF-II (insulin-like growth factors).
  • IGF-I and IGF-II insulin-like growth factors
  • hGH exists in several isoforms, the predominant form being a 22 kDa protein that can cause medical disorders both when it is hypersecreted and hyposecreted. For instance, increased secretion may cause insulin resistance, hyperglycemia, pituitary tumors and growth deficiencies such as acromegaly and giantism, whereas reduced secretion may result in growth deficiencies and dwarfism (Rodriguez et al Human Genet, 122: 1 -21 , 2007).
  • hGH under the generic name Somatropin
  • Somatropin GH replacement drugs
  • a capture molecule developed as described herein may be used in combination with such drugs to extend their half lives which would allow less frequent administration and thus reduced risk of administration-related infections as well as discomfort for patients.
  • hGH Recombinantly produced full-length hGH (Sigma-Aldhch, cat no S4776) is biotinylated and used in a phage display selection as described in Examples 2 and/or 3.
  • Candidate capture molecules are evaluated in terms of their pH sensitive interaction with the target molecule by biosensor analysis as described in Example 4. Successful candidates are further assessed in terms of their ability to interfere with GH receptor interactions. This is performed by a competition assay, for instance by biosensor analysis using a Biacore2000 instrument (Biacore).
  • the hGH is immobilized on a CM-5 chip (Biacore) by amine coupling chemistry according to the manufacturer's instructions.
  • HBS- EP pH 7.4, is used as running buffer for the analysis.
  • Injections with ligands are performed as follows: a) hGH receptor, b) the candidate capture molecule c) hGH receptor followed by the candidate capture molecule.
  • the hGH receptor is immobilized on the chip and ligands are injected as follows: 1 ) hGH, 2) the candidate capture molecule (control experiment), and 3) a premix of hGH and the candidate capture molecule.
  • the sensograms are evaluated as being additive or displaying competition / displacement events.
  • Promising candidates are defined as follows: for an extended half life application the capture molecules have a K 0 of no more than 1 x 10 ⁇ 6 for hGH at pH 5.5, and do not interfere with the interaction between hGH and the hGH receptor; for an elimination application the capture molecules have a K 0 value of no more than 1 x 10 ⁇ 7 M for hGH at pH 7.4 and with no detectable binding at pH 5.5, and when pH is changed from 7.4 to 5.5 the capture molecule rapidly dissociates from hGH. Ideally, capture molecules in the latter case also prevent binding of hGH to its receptor, by blocking one of the two interaction sites. Such candidates are further assessed in terms of their half life in vitro and in vivo as described in Example 5 and 6.
  • the pharmacodynamic effect in vivo may be investigated for instance by analyzing the serum IGF-1 levels in normal mice injected with the capture molecule or vehicle only; or study of the growth effects in hypophysectomized rats treated with the capture molecule or vehicle only.
  • Example 8 Exploiting an albumin binding capture molecule to regulate the plasma levels of active TGF31
  • TGF ⁇ Transforming growth factor beta
  • cytokines that regulate the proliferation and differentiation of cells and are important for embryonic development, wound healing and angiogenesis.
  • Activation of the T ⁇ RII/T ⁇ RI receptor complex predominantly induces the SMAD signaling pathway, a major regulator of transcription, but activation of other pathways such PI3K (phosphatidylinositol 3-kinase) and MAPK (mitogen-activated protein kinase) signaling has also been reported (reviewed in Gordon et al, Biochim Biophys Acta 1782:197-228, 2008).
  • TGF ⁇ has been implicated in both tumor suppressor and tumor promoter functions.
  • TGF ⁇ is a molecule that may be targeted both in extended half life and elimination applications.
  • the role of TGF ⁇ in tumor development is of particular interest. Overexpression of TGF ⁇ is found in most cancers, sometimes elevated by autocrine signaling, and high serum levels of the protein is associated with recurrent metastasis and poor prognosis.
  • anticancer treatments such as radiation and chemotherapy may increase the serum levels of TGF ⁇ and thus accelerate tumor progression (Biswas et al, J Clin Invest 117:1305-1313, 2007).
  • the therapeutic effect may be enhanced if the capture molecule also blocks the TGF ⁇ interaction with T ⁇ RII (which after binding to TGF ⁇ recruits T ⁇ RI).
  • T ⁇ RII which after binding to TGF ⁇ recruits T ⁇ RI
  • a separate phage selection using only the receptor-interacting region of TGF ⁇ will be pursued in parallel.
  • Three isoforms of TGF ⁇ have been identified. These are produced as a precursor from which the C-terminal 112 amino acids are cleaved and the polypeptides dimerise to form a 25 kDa active protein.
  • the T ⁇ RII-interacting region of TGF ⁇ has been mapped to the C-terminal 83-112 amino acids and in particular, residues 91-96 were identified as key residues (Qian et al, J. Biol. Chem, 29:30656).
  • TGF ⁇ i isoform
  • a capture molecule simultaneously targeting isoform 2 and 3 may be equally, or even more, interesting.
  • Recombinantly produced human TGF ⁇ 1 i-n2 (purchased from R&D systems cat. no. 100-B) and a synthetic peptide, TGF ⁇ 1 84- n2, are biotinylated and used for phage display selection as described in Example 2 and/or 3.
  • Candidate capture molecules are evaluated in terms of their pH sensitive interaction with the TGF ⁇ i I-H 2 by biosensor analysis as described in Example 4.
  • Example 7 Successful candidates are further assessed in terms of their ability to interfere with the T ⁇ RII receptor interaction in a similar manner as described in Example 7 and promising candidates are selected and tested in vitro and in vivo as outlined in Example 5 and 6.
  • the pharmacodynamic effect in vivo may be investigated for instance by comparing the tumor progression in radiation treated mice injected with the capture molecule or vehicle only.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une molécule de capture pour la modulation de la pharmacocinétique (PK) et/ou la pharmacodynamie (PD) d’une cible ayant une fonction biologique chez un mammifère, comprenant i) au moins un fragment de liaison de cible capable d’interagir avec une cible, ladite interaction étant caractérisée par une première valeur de K0; ii) au moins un fragment de liaison d’albumine capable de se lier à l’albumine, ladite liaison étant caractérisée par une deuxième valeur de K0; où ladite interaction avec une cible à une valeur de pH de 5,5 module les PK et/ou PD de ladite cible dans ledit mammifère. La présente invention concerne en outre des procédés et des utilisations d’une molécule de capture pour le traitement d’un mammifère par modulation des PK/PD d’une molécule cible.
PCT/EP2008/065691 2008-11-17 2008-11-17 Conjugués de domaine de liaison d’albumine Ceased WO2010054699A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/065691 WO2010054699A1 (fr) 2008-11-17 2008-11-17 Conjugués de domaine de liaison d’albumine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/065691 WO2010054699A1 (fr) 2008-11-17 2008-11-17 Conjugués de domaine de liaison d’albumine

Publications (1)

Publication Number Publication Date
WO2010054699A1 true WO2010054699A1 (fr) 2010-05-20

Family

ID=40342101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/065691 Ceased WO2010054699A1 (fr) 2008-11-17 2008-11-17 Conjugués de domaine de liaison d’albumine

Country Status (1)

Country Link
WO (1) WO2010054699A1 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004384A3 (fr) * 2010-07-09 2012-03-29 Affibody Ab Polypeptides
WO2013004607A1 (fr) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Polypeptides de fusion de relaxine et leurs utilisations
WO2013009539A1 (fr) * 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Polypeptides manipulés présentant une durée d'action accrue et une immunogénicité réduite
WO2013007563A1 (fr) 2011-07-08 2013-01-17 Bayer Intellectual Property Gmbh Protéines de fusion libérant de la relaxine et leurs utilisations
WO2013009545A1 (fr) * 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Polypeptides génétiquement modifiés ayant une durée d'action accrue avec une immunogénéicité réduite
WO2013143890A1 (fr) 2012-03-28 2013-10-03 Affibody Ab Administration orale
JP2013545724A (ja) * 2010-09-28 2013-12-26 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 作用持続時間が増した改変ポリペプチド
JP2014502252A (ja) * 2010-09-28 2014-01-30 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 作用持続時間が増した改変ポリペプチド
WO2014140366A1 (fr) * 2013-03-15 2014-09-18 Affibody Ab Nouveaux polypeptides
WO2014209205A1 (fr) * 2013-06-27 2014-12-31 Ge Healthcare Limited Utilisation de liants de her2
WO2016042083A1 (fr) * 2014-09-17 2016-03-24 Affibody Ab Nouveaux polypeptides
US10155792B2 (en) 2012-09-25 2018-12-18 Affibody Ab Albumin binding polypeptide
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
WO2019147954A1 (fr) * 2018-01-26 2019-08-01 Duke University Conjugués de médicament-peptidede liaison à l'albumine et méthodes de préparation et d'utilisation de ces derniers
JP2020022487A (ja) * 2013-03-15 2020-02-13 アフィボディ・アーベー 新しいポリペプチド
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
EP3785726A1 (fr) 2019-09-02 2021-03-03 Biotest AG Protéine de facteur viii à demi-vie prolongée
WO2021043757A1 (fr) 2019-09-02 2021-03-11 Biotest Ag Protéine du facteur viii à demi-vie accrue
WO2021165226A1 (fr) 2020-02-17 2021-08-26 Biotest Ag Administration sous-cutanée de facteur viii
US11135301B2 (en) 2016-09-14 2021-10-05 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
US11155584B2 (en) 2016-09-23 2021-10-26 Duke University Unstructured non-repetitive polypeptides having LCST behavior
US11458205B2 (en) 2015-08-04 2022-10-04 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
US12257308B2 (en) 2018-04-30 2025-03-25 Duke University Stimuli-responsive PEG-like polymer-based drug delivery platform

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045746A2 (fr) * 1999-12-24 2001-06-28 Genentech, Inc. Methodes et compositions permettant de prolonger les demi-vies d'elimination de composes bioactifs
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20060073152A1 (en) * 2004-10-05 2006-04-06 Genentech, Inc. Therapeutic agents with decreased toxicity
US20070077239A1 (en) * 2004-03-05 2007-04-05 The Board Of Trustees Of The University Of Illinois Peptide carrier for drug delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045746A2 (fr) * 1999-12-24 2001-06-28 Genentech, Inc. Methodes et compositions permettant de prolonger les demi-vies d'elimination de composes bioactifs
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20070077239A1 (en) * 2004-03-05 2007-04-05 The Board Of Trustees Of The University Of Illinois Peptide carrier for drug delivery
US20060073152A1 (en) * 2004-10-05 2006-04-06 Genentech, Inc. Therapeutic agents with decreased toxicity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DENNIS M S ET AL: "Albumin binding as a general strategy for improving the pharmacokinetics of proteins", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 277, no. 38, 20 September 2002 (2002-09-20), pages 35035 - 35043, XP002285300, ISSN: 0021-9258 *
LEE SANG BONG ET AL: "Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 JUN 2008, vol. 14, no. 12, 15 June 2008 (2008-06-15), pages 3840 - 3849, XP002515448, ISSN: 1078-0432 *
STORK ROLAND ET AL: "A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS NOV 2007, vol. 20, no. 11, November 2007 (2007-11-01), pages 569 - 576, XP002515447, ISSN: 1741-0126 *
TOLMACHEV VLADIMIR ET AL: "Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 67, no. 6, 15 March 2007 (2007-03-15), pages 2773 - 2782, XP002488609, ISSN: 0008-5472 *

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10329331B2 (en) 2010-07-09 2019-06-25 Affibody Ab Polypeptides
US9211344B2 (en) 2010-07-09 2015-12-15 Affibody Ab Polypeptides
EP2933262A1 (fr) * 2010-07-09 2015-10-21 Affibody AB Polypeptides
WO2012004384A3 (fr) * 2010-07-09 2012-03-29 Affibody Ab Polypeptides
US11535659B2 (en) 2010-09-28 2022-12-27 Amryt Pharmaceuticals Inc. Engineered polypeptides having enhanced duration of action
JP2013545724A (ja) * 2010-09-28 2013-12-26 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 作用持続時間が増した改変ポリペプチド
JP2014502252A (ja) * 2010-09-28 2014-01-30 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 作用持続時間が増した改変ポリペプチド
JP2017141232A (ja) * 2010-09-28 2017-08-17 アエゲリオン ファーマシューティカルズ，インコーポレイテッド 作用持続時間が増した改変ポリペプチド
WO2013004607A1 (fr) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Polypeptides de fusion de relaxine et leurs utilisations
US9382305B2 (en) 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2013009545A1 (fr) * 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Polypeptides génétiquement modifiés ayant une durée d'action accrue avec une immunogénéicité réduite
JP2014528917A (ja) * 2011-07-08 2014-10-30 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
WO2013007563A1 (fr) 2011-07-08 2013-01-17 Bayer Intellectual Property Gmbh Protéines de fusion libérant de la relaxine et leurs utilisations
CN104271588A (zh) * 2011-07-08 2015-01-07 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
US9879063B2 (en) 2011-07-08 2018-01-30 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
WO2013009539A1 (fr) * 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Polypeptides manipulés présentant une durée d'action accrue et une immunogénicité réduite
CN104271588B (zh) * 2011-07-08 2017-10-10 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
JP2014527405A (ja) * 2011-07-08 2014-10-16 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
US20160207974A1 (en) * 2011-07-08 2016-07-21 Mary Erickson Engineered polypeptides having enhanced duration of action and reduced immunogenicity
JP2016188225A (ja) * 2011-07-08 2016-11-04 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
JP2016183180A (ja) * 2011-07-08 2016-10-20 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
US20140256621A1 (en) * 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
US9382304B2 (en) 2011-07-08 2016-07-05 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action with reduced immunogenicity
JP2018052961A (ja) * 2012-03-28 2018-04-05 アフィボディ・アーベー 経口投与
WO2013143890A1 (fr) 2012-03-28 2013-10-03 Affibody Ab Administration orale
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
JP2015512902A (ja) * 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
US10155792B2 (en) 2012-09-25 2018-12-18 Affibody Ab Albumin binding polypeptide
RU2681428C2 (ru) * 2013-03-15 2019-03-06 Аффибоди Аб Новые полипептиды
JP2016511280A (ja) * 2013-03-15 2016-04-14 アフィボディ・アーベー 新しいポリペプチド
KR102191654B1 (ko) 2013-03-15 2020-12-16 애피바디 에이비 신규 폴리펩티드
KR20150132349A (ko) * 2013-03-15 2015-11-25 애피바디 에이비 신규 폴리펩티드
US10562955B2 (en) 2013-03-15 2020-02-18 Affibody Ab Polypeptides
JP2020022487A (ja) * 2013-03-15 2020-02-13 アフィボディ・アーベー 新しいポリペプチド
US9975943B2 (en) 2013-03-15 2018-05-22 Affibody Ab Polypeptides
WO2014140366A1 (fr) * 2013-03-15 2014-09-18 Affibody Ab Nouveaux polypeptides
US10646600B2 (en) 2013-06-27 2020-05-12 Imperial Innovations Limited HER2 polypeptides useful for imaging and monitoring tumors and cancers
WO2014209205A1 (fr) * 2013-06-27 2014-12-31 Ge Healthcare Limited Utilisation de liants de her2
CN105579851A (zh) * 2013-06-27 2016-05-11 通用电气健康护理有限公司 Her2结合剂的应用
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
CN107074972A (zh) * 2014-09-17 2017-08-18 阿菲博迪公司 新的多肽
EP3597661A1 (fr) * 2014-09-17 2020-01-22 Affibody AB Nouveaux polypeptides
JP2017533885A (ja) * 2014-09-17 2017-11-16 アフィボディ アクティエボラーグ 新規ポリペプチド
US10323066B2 (en) 2014-09-17 2019-06-18 Affibody Ab Neonatal Fc receptor binding dimer and methods of use
RU2725442C2 (ru) * 2014-09-17 2020-07-02 Аффибоди Аб Новые полипептиды
WO2016042083A1 (fr) * 2014-09-17 2016-03-24 Affibody Ab Nouveaux polypeptides
KR20170054440A (ko) * 2014-09-17 2017-05-17 애피바디 에이비 신규 폴리펩티드
KR102236830B1 (ko) 2014-09-17 2021-04-06 애피바디 에이비 신규 폴리펩티드
US11458205B2 (en) 2015-08-04 2022-10-04 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
US11135301B2 (en) 2016-09-14 2021-10-05 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
US12084480B2 (en) 2016-09-23 2024-09-10 Duke University Unstructured non-repetitive polypeptides having lcst behavior
US11155584B2 (en) 2016-09-23 2021-10-26 Duke University Unstructured non-repetitive polypeptides having LCST behavior
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
WO2019147954A1 (fr) * 2018-01-26 2019-08-01 Duke University Conjugués de médicament-peptidede liaison à l'albumine et méthodes de préparation et d'utilisation de ces derniers
US12296018B2 (en) 2018-01-26 2025-05-13 Duke University Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
US12257308B2 (en) 2018-04-30 2025-03-25 Duke University Stimuli-responsive PEG-like polymer-based drug delivery platform
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US11965164B2 (en) 2019-07-12 2024-04-23 Duke University Amphiphilic polynucleotides
EP3785726A1 (fr) 2019-09-02 2021-03-03 Biotest AG Protéine de facteur viii à demi-vie prolongée
WO2021043757A1 (fr) 2019-09-02 2021-03-11 Biotest Ag Protéine du facteur viii à demi-vie accrue
WO2021165226A1 (fr) 2020-02-17 2021-08-26 Biotest Ag Administration sous-cutanée de facteur viii

Similar Documents

Publication Publication Date Title
WO2010054699A1 (fr) Conjugués de domaine de liaison d’albumine
AU2021286418B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
JP7076152B2 (ja) ＩｇＧ結合ペプチドによる抗体の特異的修飾
CN113038964B (zh) 超长效胰岛素-fc融合蛋白及使用方法
CN114174348B (zh) 胰岛素类似物及其使用方法
EP3218411B1 (fr) Récepteurs d'antigène nouveaux variables (vnars) dirigé contre récepteur de transferrine et leur utilisation
Strohl Fusion proteins for half-life extension of biologics as a strategy to make biobetters
KR102002783B1 (ko) 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
US10287336B2 (en) Feline erythropoietin receptor agonists
Tan et al. Recent advances in half-life extension strategies for therapeutic peptides and proteins
EA017690B1 (ru) Мутанты fgf21 и их применение
US20190352366A1 (en) Relaxin fusion polypeptides and uses thereof
TW201625314A (zh) 降低蛋白質及肽之免疫原性之方法
JP2023507376A (ja) 超長時間作用型インスリン－ｆｃ融合タンパク質および使用法
CN114786682A (zh) 结合cd71的纤维粘连蛋白iii型结构域
WO2024084203A1 (fr) Anticorps à domaine unique se liant à l'albumine
US20210393745A1 (en) Oligomer extended insulin-fc conjugates and their medical use
US10017555B2 (en) Long-acting blood sugar decreasing fusion protein
JP2023531790A (ja) Ｆｇｆｒ１／ｋｌｂ標的化アゴニスト抗原結合タンパク質およびｇｌｐ－１ｒアゴニストペプチドとのそのコンジュゲート
US20230272031A1 (en) Insulin-fc fusion proteins and methods of use to treat cancer
WO2025181343A1 (fr) Dimères de protéine de fusion de domaine à nœud cystine
KR20250129737A (ko) 인슐린-Fc 융합 단백질 및 암 치료에 사용되는 방법
EP4240487A1 (fr) Nouvelles protéines de liaison au collagène de type ii
US20190330376A1 (en) Peptides derived from kininogen-1 for protein drugs in vivo half-life extensions
HK40076447A (en) Cd71 binding fibronectin type iii domains

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08875326

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DD 25-08-2011)

122 Ep: pct application non-entry in european phase

Ref document number: 08875326

Country of ref document: EP

Kind code of ref document: A1